# Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

> **NCT00168038** · PHASE3 · COMPLETED · sponsor: **CSL Behring** · enrollment: 58 (actual)

## Conditions studied

- Immune Thrombocytopenic Purpura

## Interventions

- **BIOLOGICAL:** Immunoglobulin Intravenous (Human)

## Key facts

- **NCT ID:** NCT00168038
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2011-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00168038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00168038, "Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00168038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*